Immunic, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $225.1M
- Price
- $16.50
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.48%
- Volume
- 147.7K
About
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Quick stats
Shares outstanding13.6M
Computed float12.1M
Float / shares88.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001280776
Websitehttps://imux.com
AI Summary
AI-generated1/32
standardbullishoperations update
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic ended the second quarter with $155.1 million in cash, sufficient to fund operations into late 2027, following a successful private placement earlier this year.
The company strengthened its leadership team by appointing Erik Lundgren as CEO and Michael Panzara as CMO, while Michael Bonney became Chair of the Board, bringing extensive experience in MS drug launches at Genentech, Biogen, and Sanofi.
Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS remain on track, with top-line data expected by the end of 2026 and a planned NDA submission in mid-2027 pending positive results.